Medscape |
FDA-Approved Drugs Have Few Postmarket Efficacy Studies
Medscape Very few postapproval studies using clinical endpoints are performed for novel drugs approved by the US Food and Drug Administration (FDA) on limited evidence for faster entry into the marketplace. The FDA approves many new agents on the basis of a ... The odds of a drug having a significant safety issue after winning FDA approval are nearly 1 in 3, study finds New ALS drug approved for Lou Gehrig's disease gives patients hope Almost one-third of FDA-approved therapeutics had postmarket safety events |
from Health - Google News http://ift.tt/2pzcfFx
EmoticonEmoticon